1. Pink Sheet
  2. >>Advanced Technologies
  3. >>AI

Why Personalized Medicine Poses HTA & Funding Challenges In England

 
• By Eliza Slawther

Personalized medicine models could benefit patients, but this approach raises tough economic and prioritization questions for health technology assessment bodies like England’s NICE.

Japan's HTA Scheme Entered Fourth Year With 14 Drugs Under Its Evaluation.
• Source: Shutterstock

England’s health technology assessment (HTA) body, NICE, must allocate resources towards medicines that “have the greatest impact on the whole population,” something that makes it “tricky” to implement personalized medicine within the National Health Service, according to Clare Morgan, director of implementation and partnerships at NICE.

“People accessing the health and care system need and want access to the best care, and the personalization route is absolutely growing,” Morgan said during a question-and-answer session at a virtual

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

AI Could Be Used ‘In The Deliberation’ Of HTA Reviews In England, Says NICE

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.

EMA’s Newly Qualified AI Tool To Boost MASH Market Dynamics

 
• By Neena Brizmohun

The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.

More from Advanced Technologies